Editorial board member Peter J Barnes (Imperial College, London, UK) discusses the rationale and findings of the late-breaking presentation he was involved with entitled: Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA-1 in mild asthma.
Questions1. What are the limitations of current reliever medications for mild asthma? (0:12)
2. What were the rationale for and objectives of the SYGMA-1 study? (0:47)
3. What were the findings of the recent post-hoc analysis of SYGMA-1? (2:01)
4. What are the next steps in the clinical development of the budesonide/formoterol Turbuhaler? (3:02)
5. What developments in asthma management have excited you most in the last year? (3:57)
Speaker disclosure: Peter J Barnes has received research funding from AstraZeneca and Boehringer Ingelheim and has been on advisory boards and given lectures for AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and Teva Pharmaceutical Industries Ltd.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.